| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and raises the price target fr...
Roche posts positive phase 3 results for giredestrant in early breast cancer, showing improved disease-free survival and a favo...
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate ...
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical com...